Pharma Phorum

JANUARY 26, 2023

2022 was a banner year for genomics. In March, the collaborative T2T consortium published the first complete telomere-to-telomere sequence of the human genome, filling in the last 8% of the 3 billion base pairs that make up our DNA.

Adverse Reactions 129

Adverse Reactions Vaccines 129

Fierce Pharma

JANUARY 26, 2023

BMS settles lawsuit with two fired employees who refused COVID vaccines kdunleavy Thu, 01/26/2023 - 14:30

Vaccines 144

Vaccines 144

Pharma Phorum

JANUARY 26, 2023

In the newest episode of the pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Jameka Hill, senior director of clinical trial health equity at Moderna.

Vaccines 105

Vaccines 105

Fierce Healthcare

JANUARY 26, 2023

Reforms needed to make voluminous insurer price data usable: report rking Thu, 01/26/2023 - 14:54

Insurance 130

Insurance 130

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

This webinar will go over the FDA's guidance on pharmacological and toxicological considerations for optimizing doses for prescription drugs.

Dosage

Pharma Phorum

JANUARY 26, 2023

Guidance on the way pharma companies communicate about prescription medicines has been updated in the UK to cover use of social media channels for the first time.

Documentation 105

Documentation Communication 105

Fierce Healthcare

JANUARY 26, 2023

How Amazon's latest pharmacy move lays the groundwork for longer-term play hlandi Thu, 01/26/2023 - 06:16

116

116

European Pharmaceutical Review

JANUARY 26, 2023

Yescarta ® ▼(axicabtagene ciloleucel; axi-cel) is now the first chimeric antigen receptor (CAR) T-cell therapy and first personalised immunotherapy to be recommended for routine use on the NHS in England.

Chemotherapy 115

Chemotherapy Immunization 115

Pharma Phorum

JANUARY 26, 2023

Roche and Boehringer Ingelheim have both formed partnerships with tech companies this week to develop and deploy wearable biosensor technology for use in clinical trials and patient monitoring.

FDA 94

FDA 94

Fierce Healthcare

JANUARY 26, 2023

How COVID-19 may have enhanced the status of preprint studies fdiamond Thu, 01/26/2023 - 15:24

111

111

Pharmaceutical Technology

JANUARY 26, 2023

Health Canada has accepted for review Valeo Pharma partner Veru’s new drug submission (NDS-CV) for Covid-19 therapy sabizabulin.

98

98

Fierce Healthcare

JANUARY 26, 2023

CMS approves waiver to enable California to offer Medicaid coverage to incarcerated individuals rking Thu, 01/26/2023 - 16:16

111

111

Pharmafile

JANUARY 26, 2023

With most drug discovery and development processes taking years, if not decades, a team of scientists have broken records with their new AI which has found a novel drug candidate for liver cancer in only 30 days.

64

64

Fierce Healthcare

JANUARY 26, 2023

DOJ charges 25 in alleged scheme that sold thousands of fake degrees to aspiring nurses dmuoio Thu, 01/26/2023 - 13:20

105

105

European Pharmaceutical Review

JANUARY 26, 2023

Packaging 86

Packaging 86

Fierce Healthcare

JANUARY 26, 2023

Private equity owns at least 130 rural hospitals, and other revelations in a sweeping new report on PE in rural healthcare agliadkovskaya Thu, 01/26/2023 - 09:45

Hospitals 98

Hospitals 98

Fierce Pharma

JANUARY 26, 2023

Abortion pill maker GenBioPro sues West Virginia over abortion ban zbecker Thu, 01/26/2023 - 14:38

84

84

Fierce Healthcare

JANUARY 26, 2023

Minnesota AG asks Sanford Health, Fairview Health Services to delay 58-hospital merger dmuoio Thu, 01/26/2023 - 16:08

98

98

PharmaVoice

JANUARY 26, 2023

Elon Musk’s takeover of Twitter has upended the ways pharma companies communicate with doctors online. Now new social strategies are emerging

Communication 59

Communication 59

Pharmafile

JANUARY 26, 2023

Merck has been planning a $1.3bn, 220,000 square foot research hub in London for six years but will finally begin construction in April this year, according to Mace, the newly-appointed principal contractor.

59

59

Pharma Phorum

JANUARY 26, 2023

In June 2022, NHS England (NHSE) and the National Institute for Health and Care Excellence (NICE) launched the Innovative Medicines Fund (IMF).

59

59

European Pharmaceutical Review

JANUARY 26, 2023

The European Medicines Agency (EMA) has published an updated Q&A document regarding ICH M10 ‘Bioanalytical Method Validation and Study Sample Analysis’.

Method Validation 84

Method Validation Documentation FDA 84

Pharma Phorum

JANUARY 26, 2023

Prostate cancer has proved an elusive target for cancer immunotherapies, and Merck & Co’s checkpoint inhibitor Keytruda is the latest to fall short in the disease in a phase 3 trial.

Chemotherapy 59

Chemotherapy Immunization FDA 59

Fierce Healthcare

JANUARY 26, 2023

Tia marks largest partnership to date with Cedars-Sinai to open women's health clinics in LA area hlandi Thu, 01/26/2023 - 08:05

81

81

European Pharmaceutical Review

JANUARY 26, 2023

Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) for adults with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer.

Chemotherapy 74

Chemotherapy 74

Fierce Healthcare

JANUARY 26, 2023

Humana to open 10 CenterWell senior primary care locations in Dallas-Fort Worth this year pminemyer Thu, 01/26/2023 - 16:59

80

80

PharmaVoice

JANUARY 26, 2023

At SFA Therapeutics, patients are the “focus” of Ira Spector’s approach to changing the course of autoimmune disease

52

52

PharmExec

JANUARY 26, 2023

This article reviews two market trends that have increased fragmentation within the healthcare market, and recommendations on how pharmaceutical and biotech companies can optimize their marketing strategies.

52

52

Pharmaceutical Commerce

JANUARY 26, 2023

Platform expected to allow customers to meet various logistics requirements, company says.

52

52

PharmExec

JANUARY 26, 2023

As pharmaceutical market access teams head into 2023, these ten trends detail why evolved preparation, thought, and engagement will be needed to meet post-pandemic marketplace expectations.

52

52

Pharmaceutical Commerce

JANUARY 26, 2023

Companies to release variety of options for this sector.

52

52

PharmExec

JANUARY 26, 2023

Webinar Date/Time: Tuesday, February 14, 2023, 9 am CT, 10 am ET, 3 pm GMT, 4 pm CET us

52

52

PharmaVoice

JANUARY 26, 2023

With a rapidly expanding oncology pipeline and a new approval in HIV, Johanna Mercier discusses Gilead’s quest to transform

52

52

Pharma Mirror

JANUARY 26, 2023

by Dodie Guadines, Viseven Regional Director, APAC Region In 2022 the APAC pharmaceutical market was estimated at $40.25 billion. At the same time, Asia-Pacific pharma players expect their businesses to grow rapidly in the upcoming year.

Vaccines 52

Vaccines 52

Pharmafile

JANUARY 26, 2023

US-based cell and gene therapy company Cell BioEngines has announced its exclusive licencing agreement with Icahn School of Medicine at Mount Sinai in New York, US, for the development and worldwide commercialisation rights for differentiating most potent immune cells from stem cells and large-scale manufacturing. read more Medical Communications

Immunization 52

Immunization Communication 52

Pharma Phorum

JANUARY 26, 2023

The European Commission has approved Daiichi Sankyo and AstraZeneca’s Enhertu as the first targeted therapy for HER2-low breast cancer, unlocking a large population of patients who could be eligible for treatment with the drug.

Chemotherapy 52

Chemotherapy FDA 52

Pharmafile

JANUARY 26, 2023

iNtRON, a bio-new drug developing venture company, has announced the completion of an efficacy evaluation study of BAL200. It has previously been awarded Orphan Drug Designation (ODD) by the FDA.

FDA 52

FDA Communication 52